<div id="readability-page-1"><div id="block-content"> <h2>Introduction: A Sector at an Operating Inflection Point</h2><p>Artificial intelligence (AI) and machine learning (ML) have moved decisively beyond the pilot stage in the life sciences industry. What once amounted to a handful of proof-of-concept models in discovery labs has become a portfolio of production capabilities spanning research and development (R&amp;D), clinical operations, manufacturing, pharmacovigilance, regulatory affairs, and commercial functions.</p><p>The strategic question facing biopharmaceutical and medical-device executives today is therefore no longer whether to invest in AI, but how to industrialize it—how to turn experimental algorithms into dependable, governed, and economically defensible systems that work inside heavily regulated workflows. The McKinsey Global Institute estimates that generative AI alone could unlock between $60 billion and $110 billion dollars in annual economic value for the pharmaceutical and medical-products industries, largely through productivity gains in discovery, clinical development, manufacturing, and commercial operations.<sup>1</sup></p><p>Capturing that value, however, requires more than model accuracy. It demands an enterprise operating model that integrates models, platforms, data products, regulatory controls, and human oversight into a single coherent capability.</p><h2>From Standalone Models to AI Operating Layers</h2><p>The first generation of ML programs in pharma and medtech treated each use case as an isolated project: choose a learning paradigm, select an algorithm, tune hyperparameters, compare metrics, and hand the model off to IT. Those technical concerns still matter, but they are no longer the binding constraint.</p><p>Three structural shifts now define the current era:</p><ul><li>First, foundation models and generative AI have dramatically broadened the range of tasks that can be automated or augmented. Instead of building one narrow model per problem, organizations increasingly adapt powerful pre-trained large language models (LLMs) through prompting, fine-tuning, or retrieval-augmented generation (RAG) to support many business processes simultaneously.</li><li>Second, AI is now experienced as a platform rather than a project. Leading life sciences companies are building internal AI services—standardized APIs, reusable orchestration components, shared embeddings, and retrieval layers—that underpin multiple applications across departments and form what is best described as an enterprise AI operating layer.</li><li>Third, governance and regulation have moved from vague aspirations into concrete engineering requirements. Documentation, traceability, explainability, and human oversight are now embedded in solution architectures and deployment gates from day one.</li></ul><p>Despite this maturation, scaling remains difficult. A McKinsey survey of more than 100 pharma and medtech leaders in late 2024 found that while 32% of organizations had taken steps to scale generative AI, only 5% considered it a competitive differentiator generating consistent financial value, and roughly three-quarters lacked a comprehensive enterprise AI strategy.<sup>2</sup></p><p>The gap between experimentation and industrialization is therefore not primarily technical; it is strategic, organizational, and regulatory.</p><h2>Classical Machine Learning: Quantified Risk in Regulated Workflows</h2><p>Classical supervised and unsupervised learning remain indispensable in regulated life sciences workflows because their outputs are quantifiable, auditable, and defensible. In manufacturing, supervised models can estimate the probability that a production lot will fail final inspection using historical data on equipment settings, calibration parameters, in-process measurements, supplier lots, environmental conditions, and operator shifts.</p><p>The output is never intended to autonomously discard lots; it prioritizes human-led interventions such as enhanced sampling, engineering review, or temporary holds. In pharmacovigilance, supervised models trained on historical safety data score incoming adverse-event reports for seriousness, unexpectedness, and probable causal relevance, allowing safety physicians to focus on the cases most likely to contain a true signal.</p><p>Unsupervised learning, meanwhile, has become a discovery tool: patient embeddings that combine genomic, biomarker, imaging, and treatment-pattern data can reveal clinically meaningful subpopulations, while clustering of providers or trial sites can guide engagement strategy and site selection.</p><p>Deep learning extends these capabilities to visual, textual, and sequential data. Convolutional neural networks inspect vials, syringes, fill levels, and labels on parenteral lines at thousands of units per minute, tolerating variation in lighting and geometry that defeats traditional machine vision.</p><p>Transformer-based natural-language models extract data from clinical source documents, flag inconsistencies, suggest MedDRA coding for adverse events, and surface protocol deviations early. In decentralized clinical trials, deep models process continuous wearable data—heart rate variability, activity, sleep, and temperature—to detect anomalies and predict dropout risk. The unifying principle is that these models must be treated as production software requiring rigorous validation rather than as experimental curiosities.</p><h2>Foundation Models and Generative AI in the Pharmaceutical Enterprise</h2><p>Generative AI is reshaping the document-heavy functions of regulatory affairs, quality, legal, and compliance. RAG-enabled LLM assistants now search for internal repositories of standard operating procedures, prior submissions, inspection responses, and external guidance to synthesize answers anchored in source materials.</p><p>The value is not the replacement of regulatory or quality specialists, but the elimination of search friction, which allows experts to spend more time on strategic positioning and substantive review. Similar copilots assist scientists in summarizing literature on a therapeutic target, propose compounds that match desired pharmacophore traits, help clinical operations managers diagnose enrollment lag at underperforming sites, support field-service engineers in ranking probable root causes for device error codes, and draft narratives and coding suggestions for pharmacovigilance case processors.</p><p>Early evidence suggests the impact on drug discovery is substantial. A 2024 analysis of the clinical pipelines of AI-native biotechnology companies found that AI-discovered molecules achieved a Phase I success rate of 80% to 90%, substantially higher than historical industry averages in the range of 40% to 65%, while Phase II success rates of approximately 40% were comparable to historic norms.<sup>3</sup></p><p>Similar productivity gains are emerging in clinical operations: industry research indicates that AI-driven patient matching and outreach can reduce recruitment timelines by as much as 50%, and analysts project that AI could be embedded in 60% to 70% of clinical trials by 2030, with potential annual savings of 20 to 30 billion U.S. dollars.<sup>4</sup> Across all of these applications, the design rule is constant: AI recommends, humans decide.</p><h2>Mapping AI Use Cases Across the Life Sciences Value Chain</h2><p>AI is no longer confined to a small innovation team; it is becoming an enterprise capability that touches every domain of the value chain. The table below summarizes representative use cases, dominant techniques, and the primary business outcomes targeted in each domain.</p><h2>Industrial-Grade Machine Learning Operations (MLOps) and Data as a Managed Product</h2><p>Production AI in life sciences requires a formal lifecycle that mirrors disciplined software engineering: intake, data assessment, model development, validation, deployment, monitoring, retraining, and retirement. Every stage must be versioned and auditable. A predictive quality model that achieves 94% accuracy in a notebook is not yet a production system.</p><p>Deployment requires governed data infrastructure, a model registry storing dependencies and approvers, automated quality gates that trigger retraining only when new model performance remains within acceptable bounds, dashboards that monitor accuracy and false-positive or false-negative rates stratified by lot characteristics, drift detection that flags supplier or process changes, and full audit trails recording every prediction, model version, and corrective action. If a regulator asks why a specific lot was flagged on a particular date, the organization must be able to reconstruct the exact model version, training-data snapshot, decision threshold, and business action in effect at that moment.</p><p>Equally important is the treatment of data as a managed product rather than a project byproduct. An adverse event data product, for example, can integrate post-market surveillance reports, clinical safety databases, healthcare-provider complaints, and external sources such as the FDA Manufacturer and User Facility Device Experience (MAUDE) database.</p><p>With clear ownership, standardized definitions, governed access, and version control, the same data product feeds pharmacovigilance signal detection, regulatory submissions, post-market surveillance, and research analyses without recreating ad hoc extracts for every initiative. This shift from project data to product data is one of the highest-leverage investments an AI program can make.</p><h2>Governance, Regulation, and Responsible AI</h2><p>Governance is no longer a separate ethics exercise; it is part of evidence generation, quality assurance, and risk management. Most large life sciences organizations now operate formal oversight structures, including AI ethics committees, model risk management functions adapted from financial services, clinical evidence and validation committees, and data governance boards.</p><p>Their purpose is not to block innovation but to ensure that high-impact systems are designed with clear escalation paths, appropriate human oversight, and defensible documentation. The regulatory landscape is crystallizing rapidly.</p><p>As of August 2024, the FDA had authorized roughly 950 AI- or ML-enabled medical devices, and subsequent industry analyses have tracked the total to well over 1,400 devices, with the large majority concentrated in radiology and cardiology.<sup>5</sup> FDA expectations now include 21 CFR Part 11 controls for traceable electronic records and audit trails, Software as a Medical Device (SaMD) requirement for clinical validity and explainability, and Predetermined Change Control Plans (PCCPs) that distinguish minor model updates from changes requiring revalidation or new submissions.<sup>6</sup></p><p>In January 2025, the FDA issued draft guidance on the use of AI to support regulatory decision-making for drug and biological products, introducing a risk-based credibility framework intended to help sponsors justify AI-derived information used in submissions.<sup>7</sup> In Europe, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) published a joint Data and AI workplan covering 2025 to 2028, complementing the EMA reflection paper on AI in the medicinal product lifecycle.<sup>8</sup></p><p>Together, these instruments signal that regulators now expect AI-enabled systems to be engineered, validated, monitored, and defended across their lifecycle, not merely trained.</p><h2>Translating Strategy into Measurable Outcomes</h2><p>Industrialized AI programs anchor every initiative in an explicit business outcome. The table below illustrates the order of magnitude of value that life sciences leaders are increasingly using to size and prioritize their AI portfolios.</p><h2>Common Pitfalls and How Leaders Avoid Them</h2><p>Several recurring pitfalls separate organizations that scale AI from those that stall.</p><ol><li>The first pitfall is overreliance on generative AI without meaningful human review, which is particularly dangerous when AI-generated content flows into regulatory submissions or safety decisions. The remedy is to design workflows in which AI produces a draft or recommendation, a qualified human reviews and explicitly approves it, and traceability is preserved between the AI suggestion and the human decision.</li><li>The second pitfall is underestimating the last mile of integration with legacy enterprise resource planning, quality management, laboratory information management, and electronic data capture systems. Leaders plan for integration from the outset, involving IT operations and system integration teams early.</li><li>The third pitfall is governance fragmentation, in which each business unit procures its own AI tools and connects independently to external models, producing inconsistent controls and duplicated effort. A federated model that combines central platforms and standards with local autonomy for innovation typically outperforms both extreme centralization and uncoordinated decentralization.</li><li>The fourth pitfall is insufficient attention to fairness and bias: models that perform well in aggregate may disadvantage specific demographic subgroups when training data are incomplete. Stratified performance analysis across age, sex, race, ethnicity, and disease stage must therefore be treated as a non-negotiable part of validation.</li><li>The fifth pitfall is neglecting maintenance after deployment, as models inevitably drift when real-world data diverge from training conditions. Automated drift detection, retraining triggers, and dedicated MLOps personnel are essential, not optional.</li></ol><h2>Conclusion: Durable Advantage Comes from Engineered, Governed Systems</h2><p>AI is now a persistent organizational capability rather than a one-time transformation. The life science organizations that will lead the next decade are not those that deploy the most models, but those that deploy systems that are scientifically credible, clinically defensible, regulatorily traceable, and operationally sustained.</p><p>Durable advantage emerges when advanced analytics are combined with disciplined engineering, governed data products, human accountability, and an explicit link to business and clinical outcomes. For pharmaceutical and medical-device executives, the practical agenda is clear: align AI investments with measurable outcomes, build coherent platforms instead of point solutions, invest in multidisciplinary teams and AI literacy, and treat governance and lifecycle monitoring as integral features of every AI-enabled system.</p><p>Organizations that internalize these principles will convert AI from a portfolio of pilots into a compounding source of value.</p><p><em>Disclaimer: The views expressed in the article are those of the authors and not of the organizations they represent.</em></p><p><strong>About the Author</strong></p><p><em><strong>Partha Anbil</strong> is at the intersection of the Life Sciences industry and Management Consulting. He is currently SVP, Life Sciences, at Coforge Limited, a $2.5B multinational digital solutions and technology consulting services company. He held senior leadership roles at WNS, IBM, Booz &amp; Company, Symphony, IQVIA, KPMG Consulting, and PWC. Mr. Anbil has consulted with and counseled Health and Life Sciences clients on structuring solutions to address strategic, operational, and organizational challenges. He is a diplomat/fellow at MIT CSAIL. He is a healthcare expert member of the World Economic Forum (WEF). He is also a Life Sciences industry advisor at MIT, his alma mater. He was a member of the IBM Industry Academy, a very selective group of professionals inducted into the academy by invitation only, the highest honor at IBM.</em></p><p><strong>References</strong></p><p>1. McKinsey &amp; Company. Generative AI in the pharmaceutical industry: Moving from hype to reality. January 9, 2024. </p><p>2. McKinsey &amp; Company. Scaling gen AI in the life sciences industry. January 10, 2025. </p><p>3. Jayatunga, M. K. P., Ayers, M., Bruens, L., Jayanth, D., &amp; Meier, C. How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons. Drug Discovery Today, 29(6), 104009, June 2024. </p><p>4. BCC Research. AI in Clinical Trials Poised for Rapid Growth with a 22.6% CAGR. January 2026. </p><p>5. MedTech Dive. The number of AI medical devices has spiked in the past decade. October 9, 2024. </p><p>6. U.S. Food and Drug Administration. Artificial Intelligence in Software as a Medical Device. Updated March 25, 2025. </p><p>7. U.S. Food and Drug Administration. Draft Guidance: Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products. January 6, 2025. </p><p>8. European Medicines Agency &amp; Heads of Medicines Agencies. Data and AI in medicines regulation to 2028 (Network Data Steering Group workplan 2025–2028). May 7, 2025.</p> </div></div>

<p>The life sciences industry is at an inflection point with AI and ML moving beyond pilot stages to become integral in R&D, clinical operations, and manufacturing. McKinsey estimates generative AI could unlock $60-$110 billion annually for pharmaceuticals. However, only 5% of organizations see it as a competitive advantage. The shift from isolated ML projects to enterprise AI operating layers is crucial, emphasizing governance and integration. Classical ML remains vital for regulated workflows, while generative AI enhances regulatory and operational efficiency.</p>

<![CDATA[Industrializing Machine Learning and Artificial Intelligence in Life Sciences]]>